MARKET

BFRIW

BFRIW

Biofrontera
NASDAQ
0.0501
-0.0133
-20.98%
Closed 15:46 02/11 EST
OPEN
0.0635
PREV CLOSE
0.0634
HIGH
0.0635
LOW
0.0501
VOLUME
250
TURNOVER
0
52 WEEK HIGH
0.2770
52 WEEK LOW
0.0251
MARKET CAP
--
P/E (TTM)
-0.0272
1D
5D
1M
3M
1Y
5Y
1D
FDA Accepts Biofrontera sNDA Filing for Ameluz PDT in Superficial Basal Cell Carcinoma
Reuters · 21h ago
BIOFRONTERA INC - FDA SETS PDUFA DATE FOR SEPTEMBER 28, 2026
Reuters · 21h ago
Biofrontera meldet erfolgreiche Phase-3-Studie für Ameluz bei aktinischer Keratose an Extremitäten, Hals und Rumpf
Reuters · 2d ago
Biofrontera Reports Positive Phase 3 Results for Ameluz PDT in Treating Actinic Keratoses Beyond Face and Scalp
Reuters · 2d ago
BIOFRONTERA INC - TO SUBMIT SNDA TO FDA IN Q3 2026
Reuters · 2d ago
Weekly Report: what happened at BFRIW last week (0202-0206)?
Weekly Report · 3d ago
Biofrontera Announces Positive Results in Phase 3 Study of Ameluz® PDT for Actinic Keratoses on the Extremities, Neck, and Trunk, Meeting Primary Endpoint
Barchart · 3d ago
Weekly Report: what happened at BFRIW last week (0126-0130)?
Weekly Report · 02/02 09:45
More
About BFRIW
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.

Webull offers Biofrontera Inc stock information, including NASDAQ: BFRIW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, BFRIW stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading BFRIW stock methods without spending real money on the virtual paper trading platform.